HEPATOL INT 润色咨询

Hepatology International

出版年份：2007 年文章数：714 投稿命中率： 开通期刊会员，数据随心看

出版周期：Quarterly 自引率：3.4% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-06-25 嘻嘻号 来自江苏省

    2周了，状态还是正在提交给杂志，太慢了

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2024-11-01 ms1000001073912817 来自陕西省

    稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2024-10-11 ms5000000711521518 来自新疆

    一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2024-06-11 ms8000000674248726 来自浙江省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：脂肪肝;临床
    经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2024-04-22 ms4000001768031770 来自广东省

    想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-12-28 ms4000001768031770 来自广东省

    2023降区了，成3区的了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-14 ms6000001864840275

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肝脏
    经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2021-03-01 1dd96cb3m86(暂无匿称)

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-04-10 苏苏sci

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肝癌;临床
    经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2144690, encodeId=efb9214469024, content=2周了，状态还是正在提交给杂志，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/14/adc0803ff06d9f6fc9d2bfc21391f246.jpg, createdBy=ac125183861, createdName=嘻嘻号, createdTime=Sun Jun 25 20:53:54 CST 2023, time=2023-06-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2234541, encodeId=a2e92234541fa, content=稿件需要一定的创新性，对于我这个小领域（自免肝）来说是比较难投的，课题组第3篇投中这杂志的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Fri Nov 01 11:41:40 CST 2024, time=2024-11-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2230298, encodeId=a6e722302984d, content=一般submit to journal 持续多久 ，初审时间多长，有没有投过的便宜分享经验！ 谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Fri Oct 11 10:13:20 CST 2024, time=2024-10-11, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2209329, encodeId=a6fd2209329c9, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：脂肪肝;临床<br>经验分享：感觉临床大样本数据会比较有优势，under review花了4个多月的时间，非常非常慢，但好在意见都还可以，修回后一两周就通过了，后面进展就很快了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60608443753, createdName=ms8000000674248726, createdTime=Tue Jun 11 11:30:36 CST 2024, time=2024-06-11, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2199745, encodeId=3e782199e45f6, content=想问下大家都多久见刊的？我的接收5个月了还没见刊，但是看到同一个月接收的文章有的见刊了，有的比我晚几个月的也见刊了，发了邮件给期刊也没有回应, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Mon Apr 22 09:52:21 CST 2024, time=2024-04-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177854, encodeId=498321e785456, content=2023降区了，成3区的了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e43b5476402, createdName=ms4000001768031770, createdTime=Thu Dec 28 19:56:56 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1238700, encodeId=a0081238e00a3, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏<br>经验分享：记录一下helen小硕的第一篇SCI！投稿时间是2022年4月25日；最终接受的时间是2022年8月12日。首先杂志的审稿时间还是挺快的，有3个审稿人，送审之后不到3周就开始了第一次修回（大修）；修回之后之后仅有一个审稿人提出需要有一些基础的研究（小修），给了一个月的时间，补了一些基础实验，修回之后大概等了2-3周的时间，给出了最终接受的结果。杂志整体还是比较nice，希望每个科研人文章都可以顺利接受！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94b05588321, createdName=ms6000001864840275, createdTime=Sun Aug 14 23:17:23 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944315, encodeId=e47f944315e8, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：经过1个月大修，三个审稿人。小修终于接受，前后经历3个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Mar 01 02:01:11 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210026, encodeId=49dc12100268b, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肝癌;临床<br>经验分享：去年12月投的，前后返修2次，审稿人问题很刁钻，昨天中的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c5dc5561694, createdName=苏苏sci, createdTime=Sun Apr 10 13:20:49 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240015, encodeId=62a212400155c, content=偏重的研究方向：手术;肝癌;临床<br>经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Sat Aug 20 19:41:05 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-20 YJJJJJ

    偏重的研究方向：手术;肝癌;临床
    经验分享：临床文章。投稿后一个半月大修，基本没补什么东西，把图表和文本内容调整了一下，一个月后接收。

    3

    展开3条回复
共70条页码: 1/7页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分